Tetra Radar · FDA Approvals · Decision date
DTX401: FDA decision date
Ultragenyx Pharmaceutical Inc (RARE) · 23 August 2026
The FDA granted the BLA Priority Review and assigned a Prescription Drug User Fee Act (PDUFA) action date of August 23, 2026.
Source: 10-Q of 5 August 2026
The FDA approved it on 19 August 2026.
The FDA approved GENGLYCOS to reduce daily cornstarch intake as an adjunct to nutritional management in adult and pediatric patients 8 years of age and older with glycogen storage disease type Ia (GSDIa).
Ultragenyx Pharmaceutical Inc on Tetra Radar
A PDUFA date is the date by which the FDA has said it will decide on an application. Dates can move, and a decision is not an approval. Tetra Radar observes public information for research purposes. It does not provide investment advice.